Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Why IonQ Stock Jumped 12.4% This Morning (Fool) +++ IONQ Aktie -3,79%

REGENERON Aktie

 >REGENERON Aktienkurs 
696 EUR    -1.6%    (TradegateBSX)
Ask: 700 EUR / 14 Stück
Bid: 694.8 EUR / 14 Stück
Tagesumsatz: 110 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
REGENERON Aktie über LYNX handeln
>REGENERON Performance
1 Woche: -2,0%
1 Monat: +3,1%
3 Monate: +31,4%
6 Monate: +6,6%
1 Jahr: +46,7%
laufendes Jahr: +4,9%
>REGENERON Aktie
Name:  REGENERON PHARMACEUTICALS
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US75886F1075 / 881535
Symbol/ Ticker:  RGO (Frankfurt) / REGN (NASDAQ)
Kürzel:  FRA:RGO, ETR:RGO, RGO:GR, NASDAQ:REGN
Index:  S&P500, Nasdaq100
Webseite:  https://www.regeneron.com..
Profil:  Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, develops, manufactures, and commercializes medicines for people with serious diseases. Its portfolio spans treatments in eye care, immunology, oncology, cardiovascular and met..
>Volltext..
Marktkapitalisierung:  73386.21 Mio. EUR
Unternehmenswert:  68743.11 Mio. EUR
Umsatz:  13377.86 Mio. EUR
EBITDA:  4049.52 Mio. EUR
Nettogewinn:  3727.7 Mio. EUR
Gewinn je Aktie:  36.09 EUR
Schulden:  2330.81 Mio. EUR
Liquide Mittel:  2123.62 Mio. EUR
Operativer Cashflow:  4031.35 Mio. EUR
Bargeldquote:  1.45
Umsatzwachstum:  12.73%
Gewinnwachstum:  0.14%
Dividende je Aktie:  3.18 EUR
Dividendenrendite:  0.45%
Dividendenschätzung:  0.47%
Div. Historie:  18.08.26 - 0.80548596€
20.05.26 - 0.808306€
>weitere anzeigen...
Insiderhandel:  3 Insider verkauften innerhalb der letzten 30 Tage Aktien im Wert von 2.841.007 Euro.
Suchwörter:  REGENERON
Letzte Datenerhebung:  08.09.26
>REGENERON Kennzahlen
Aktien/ Unternehmen:
Aktien: 101.14 Mio. St.
Frei handelbar: 97.99%
Leerverk. Aktien: 2.37%
Rückkaufquote: 2.98%
Mitarbeiter: 15410
Umsatz/Mitarb.: 0.8 Mio. EUR
Analysten:
Analystenrating: Buy
Kursziel: 2.68%
Bewertung:
KGV: 20.08
KGV lG: 15.24
KUV: 5.62
KBV: 2.65
PEG-Ratio: 10.41
EV/EBITDA: 16.98
Rentabilität:
Bruttomarge: 81.46%
Gewinnmarge: 27.86%
Operative Marge: 26.87%
Managementeffizenz:
Gesamtkaprendite: 10.83%
Eigenkaprendite: 14.04%
>REGENERON Peer Group
 
07.09.26 - 19:21
 REGN 1-WEEK DEADLINE ALERT: Regeneron Pharmaceuticals, Inc. Investors Alerted to September 14, 2026 Lead Plaintiff Deadline in Class Action Lawsuit (PR Newswire)
 
SAN FRANCISCO, Sept. 7, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors in Regeneron Pharmaceuticals (NASDAQ: REGN) that a securities class action lawsuit has been filed after its surprising revelations concerning a Phase 3 clinical trial of a therapy intended to......
04.09.26 - 21:00
 Vertex vs. Regeneron: Which Biotech Giant Is the Better Buy Right Now? (Fool)
 
They could both outperform the market over the medium term, but one appears to have a clear edge....
04.09.26 - 03:01
 Insiderhandel: Aufsichtsrat verkauft Aktien von Regeneron Pharmaceuticals im Wert von 340000 USD (Insiderkauf)
 
Guarini, Kathryn - Aufsichtsrat - Tag der Transaktion: 2026-09-02...
04.09.26 - 03:01
 Insiderhandel: EVP Commercial verkauft Aktien von Regeneron Pharmaceuticals im Wert von 969708 USD (Insiderkauf)
 
Mccourt, Marion - Vorstand - Tag der Transaktion: 2026-09-03...
04.09.26 - 03:01
 Insiderhandel: EVP Commercial verkauft Aktien von Regeneron Pharmaceuticals im Wert von 1032750 USD (Insiderkauf)
 
Mccourt, Marion - Vorstand - Tag der Transaktion: 2026-09-02...
04.09.26 - 01:12
 REGN INVESTOR ALERT: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead the Regeneron Class Action Lawsuit (PR Newswire)
 
SAN DIEGO, Sept. 3, 2026 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) common stock between August 1, 2025 and May 15, 2026, inclusive (the "Class Period"), have until September 14, 2026 to seek......
03.09.26 - 21:21
 REGN ALERT: Hagens Berman Alerts Regeneron Pharmaceuticals, Inc. (REGN) Investors to Pending Securities Fraud Class Action Amid Disclosures About Key Trial′s Protocol and Ultimate Failure (PR Newswire)
 
SAN FRANCISCO, Sept. 3, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors in Regeneron Pharmaceuticals (NASDAQ: REGN) that a securities class action lawsuit has been filed after its surprising revelations concerning a Phase 3 clinical trial of a therapy intended to......
03.09.26 - 16:09
 REGN Investor Alert: Regeneron Pharmaceuticals, Inc. Securities Class Action Notice - Contact SueWallSt (PR Newswire)
 
Market impact notice: REGN shares allegedly lost $102.09 from the Class Period high after disclosures about a Phase III Fianlimab-Libtayo protocol change and failed primary endpoint challenged earlier positive trial-risk messaging. NEW YORK, Sept. 3, 2026 /PRNewswire/ -- SueWallSt......
02.09.26 - 16:15
 REGN Deadline Alert: Levi & Korsinsky Reminds Regeneron Pharmaceuticals (REGN) Investors of Securities Class Action Deadline on September 14, 2026 (PR Newswire)
 
Important Notice Regarding Alleged Phase III Fianlimab-Libtayo Clinical Trial Risk Misrepresentations. The lawsuit alleges Regeneron investors overpaid while the Company characterized slowing event accrual as potentially favorable, even as the study allegedly faced heightened risk of......
01.09.26 - 18:24
 INVESTOR DEADLINE: Regeneron Pharmaceuticals, Inc. (REGN) Investors with Substantial Losses Have Opportunity to Lead the Regeneron Class Action Lawsuit Before September 14, 2026 Deadline (PR Newswire)
 
SAN FRANCISCO, Sept. 1, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors in Regeneron Pharmaceuticals (NASDAQ: REGN) that a securities class action lawsuit has been filed after its surprising revelations concerning a Phase 3 clinical trial of a therapy intended to......
28.08.26 - 18:09
 Regeneron Pharmaceuticals, Inc. (REGN) Investors: Securities Fraud Class Action Filed, Contact Hagens Berman Before September 14, 2026 Lead Plaintiff Deadline (PR Newswire)
 
SAN FRANCISCO, Aug. 28, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors in Regeneron Pharmaceuticals (NASDAQ: REGN) that a securities class action lawsuit has been filed after its surprising revelations concerning a Phase 3 clinical trial of a therapy intended to......
27.08.26 - 22:09
 INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - REGN (PR Newswire)
 
NEW YORK, Aug. 27, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980,......
27.08.26 - 16:12
 REGN DEADLINE: SueWallSt Reminds Regeneron Pharmaceuticals, Inc. Investors of Upcoming Securities Class Action Deadline (PR Newswire)
 
Control-person liability allegations focus on Regeneron executives' alleged authority over public clinical-trial statements and SEC disclosures as REGN shares fell $102.09 from the Class Period high. NEW YORK, Aug. 27, 2026 /PRNewswire/ -- SueWallSt notifies investors in Regeneron......
27.08.26 - 00:18
 Regeneron Pharmaceuticals, Inc. (REGN) Investors: September 14, 2026 Lead Plaintiff Deadline in Class Action Lawsuit (PR Newswire)
 
SAN FRANCISCO, Aug. 26, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors in Regeneron Pharmaceuticals (NASDAQ: REGN) that a securities class action lawsuit has been filed after its surprising revelations concerning a Phase 3 clinical trial of a therapy intended to......
26.08.26 - 16:09
 REGN Shareholder Alert: Regeneron Pharmaceuticals, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact Levi & Korsinsky (PR Newswire)
 
This promise-vs-reality notice focuses on allegations that Regeneron promoted Phase I Fianlimab-Libtayo results and practice-changing expectations while the Phase III study allegedly faced heightened statistical and clinical failure risk. NEW YORK, Aug. 26, 2026 /PRNewswire/ -- Levi &......
25.08.26 - 13:15
 Veeva Vault CRM Selected by Regeneron (PR Newswire)
 
Leading biopharma company selects agentic CRM for life sciences to generate Commercial Evidence PLEASANTON, Calif., Aug. 25, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Regeneron Pharmaceuticals has committed to Veeva Vault CRM globally. With Vault CRM, Regeneron......
24.08.26 - 18:39
 Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Regeneron Class Action Lawsuit - Hagens Berman Sobol Shapiro LLP (PR Newswire)
 
SAN FRANCISCO, Aug. 24, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors in Regeneron Pharmaceuticals (NASDAQ: REGN) that a securities class action lawsuit has been filed after its surprising revelations concerning a Phase 3 clinical trial of a therapy intended to......
21.08.26 - 10:42
 Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - REGN (PR Newswire)
 
LOS ANGELES, Aug. 21, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ: REGN) violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated......
20.08.26 - 19:06
 REGN Shareholder Alert: September 14, 2026 Lead Plaintiff Deadline in Regeneron Pharmaceuticals Securities Class Action - Contact SueWallSt (PR Newswire)
 
This Regeneron analyst reaction focuses on analysts' reassessment of the Phase III Fianlimab-Libtayo Study after a protocol amendment raised concerns about statistical significance and potential impact on Regeneron's pipeline and future growth expectations. NEW YORK, Aug. 20, 2026......
20.08.26 - 18:15
 Regeneron Secures FDA Approval for Rare Genetic Disorder Drug (Zacks)
 
REGN's Pasatru wins FDA approval for FOP, cutting new HO lesions by 90% or more and reducing clinician-assessed flare-ups....
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Bei einem großen Dichter hat man das Gefühl, als ob Dinge emportauchen, die im Chaos stecken geblieben sind. - Christian Friedrich Hebbel
>Aktienauflistung | >Aktienscreener | >Aktienkennzahlen | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!